By Counterforce Health Team in Alecensa (alectinib) —

How to Get Alecensa (alectinib) Covered by UnitedHealthcare in New Jersey: 2025 Step Therapy Rules, Appeals Process, and Timeline Requirements

Answer Box: Getting Alecensa Covered in New Jersey

New Jersey's 2025 laws give you stronger protections for getting Alecensa (alectinib) approved by UnitedHealthcare. Starting January 1, 2026, state-regulated plans must grant step therapy exceptions within 24-72 hours if prior ALK inhibitors caused harm, were ineffective, or you're stable on current therapy. UnitedHealthcare must respond to urgent prior authorizations within 24 hours under New Jersey law.

Your fastest path: 1) Ensure ALK-positive test results are documented, 2) Submit prior authorization via UnitedHealthcare provider portal with complete clinical justification, 3) If denied, request step therapy exception citing New Jersey Assembly Bill A1825 criteria.

Take action today: Contact your oncologist to gather ALK test results and treatment history for your prior authorization request.

Table of Contents

Why New Jersey's State Rules Matter

New Jersey has some of the strongest patient protection laws in the country, especially for cancer treatments like Alecensa. These state regulations override many insurance company policies and give you specific rights that vary by plan type.

State-regulated plans (including UnitedHealthcare individual marketplace plans, small group plans, and New Jersey Medicaid) must follow New Jersey's strict timeline and step therapy rules. Self-funded employer plans may not be subject to all state protections due to federal ERISA laws, but many voluntarily comply.

The key difference: New Jersey law now requires medical exceptions to step therapy protocols when clinically justified, with mandatory rapid response times that protect cancer patients from dangerous delays.

2025 Timeline Requirements

New Jersey's new prior authorization law, effective January 2025, sets strict deadlines that UnitedHealthcare must meet:

  • Urgent requests: 24 hours maximum response time
  • Non-urgent requests: 72 hours maximum response time
  • Long-term cancer therapy approvals: Must remain valid for at least 180 days

For Alecensa specifically, UnitedHealthcare typically processes NCCN-compliant regimens quickly when complete documentation is provided. However, New Jersey's 24-hour urgent timeline takes precedence for time-sensitive cancer cases.

Tip: Always mark your request as "urgent" if any delay could impact your health or treatment timeline.

Step Therapy Protections

New Jersey's Assembly Bill A1825, effective January 1, 2026, provides powerful step therapy exceptions for ALK inhibitors like Alecensa. UnitedHealthcare must grant exceptions within 24-72 hours if:

  • The required drug is contraindicated or likely to cause adverse reactions
  • Previous ALK inhibitors were ineffective or less effective based on your clinical characteristics
  • All formulary drugs in the protocol have been tried and were ineffective or harmful
  • You're stable on current therapy and switching may not be medically appropriate

These protections specifically help patients who need immediate access to Alecensa without trying cheaper alternatives first.

Coverage Requirements at a Glance

Requirement What It Means Where to Find It Source
Prior Authorization Required for all Alecensa prescriptions UnitedHealthcare Provider Portal UHC Exchange Coverage
ALK Testing Must document ALK-positive result with FDA-approved test Pathology report required UHC Molecular Testing Policy
Formulary Status Specialty tier, high copay/coinsurance Plan formulary document 2025 NJ Prescription Drug List
Step Therapy May require trying other ALK inhibitors first Exception available under NJ law NJ Step Therapy Reform
Appeals Deadline 180 days from denial for internal appeals Denial letter instructions Standard UHC policy
External Review 4 months from final denial for IHCAP NJ Department of Banking & Insurance IHCAP Information

Step-by-Step: Fastest Path to Approval

1. Gather Required Documentation (Patient + Clinic)

You need: Insurance card, ALK-positive pathology report, complete treatment history, current medications list Timeline: Same day Submit to: Your oncologist's office

2. Provider Submits Prior Authorization (Clinic)

What's included: ALK test results, diagnosis with staging, NCCN guideline citation, prior therapy failures/contraindications How to submit: UnitedHealthcare Provider Portal or call 1-800-711-4555 Timeline: Within 24-72 hours for response under New Jersey law

3. If Denied, Request Step Therapy Exception (Clinic)

Documentation needed: Letter citing New Jersey Assembly Bill A1825, specific medical reasons why alternatives are inappropriate Submit via: Same portal with "step therapy exception" clearly marked Timeline: 24-72 hours for decision

4. Internal Appeal if Exception Denied (Patient or Clinic)

Required documents: Original denial letter, additional clinical evidence, peer-reviewed studies supporting Alecensa use Submit to: Address/portal specified in denial letter Timeline: 180 days from denial to file

5. External Review Through IHCAP (Patient)

When eligible: After completing UnitedHealthcare's internal appeals process Submit to: Maximus Federal Services (contracted by New Jersey) Timeline: 4 months from final denial to file

Common Denial Reasons & How to Fix Them

Denial Reason How to Overturn Required Documentation
Missing ALK test Submit FDA-approved ALK testing results Pathology report with test methodology
Step therapy required File exception under NJ A1825 citing contraindications/ineffectiveness Medical records showing prior failures
Not medically necessary Provide NCCN guideline citation and clinical justification Peer-reviewed studies, treatment guidelines
Quantity limits exceeded Document appropriate dosing based on FDA labeling Prescriber attestation, dosing rationale
Non-formulary status Request formulary exception with clinical superiority evidence Comparative effectiveness data

Appeals Process in New Jersey

UnitedHealthcare follows a structured appeals process that New Jersey law makes more consumer-friendly:

Internal Appeals (1-2 Levels)

  • First level: Submit within 180 days of denial
  • Review by: UnitedHealthcare medical director or oncology specialist
  • Timeline: 30 days standard, 72 hours expedited
  • Required: Original denial letter, new clinical evidence, provider letter

Peer-to-Peer Review

Before formal appeals, request a peer-to-peer review where your oncologist speaks directly with UnitedHealthcare's medical director. This often resolves denials faster than written appeals.

To request: Call the number on your denial letter and ask for peer-to-peer review scheduling.

External Review Through IHCAP

New Jersey's Independent Health Care Appeals Program (IHCAP) provides an impartial review when UnitedHealthcare's internal appeals fail.

Eligibility: Medical necessity denials (not benefit exclusions), completed internal appeals, New Jersey-regulated plan

Process:

  1. Submit IHCAP application within 4 months of final denial
  2. Maximus Federal Services conducts preliminary review (5 business days)
  3. Independent physician panel reviews case (45 days maximum)
  4. Decision is binding on UnitedHealthcare

Cost: Free to patients; UnitedHealthcare pays all review costs

Success rates: Approximately 50% of external appeals nationwide favor consumers, with cancer cases often having higher success rates.

For IHCAP applications and guidance, contact the New Jersey Department of Banking and Insurance at 1-800-446-7467.

When to Escalate to State Regulators

Contact New Jersey regulators if UnitedHealthcare violates state law requirements:

New Jersey Department of Banking and Insurance

File a complaint for:

  • Missing the 24-hour urgent response deadline
  • Refusing valid step therapy exceptions under A1825
  • Procedural violations during appeals
  • Failure to provide required notices or forms

Continuity of Care Protections

New Jersey provides specific protections for cancer patients during insurance transitions:

90-Day Minimum Coverage: If your plan changes formularies or you switch insurance during active cancer treatment, you're entitled to at least 90 days of continued coverage for ongoing therapy.

How to invoke: Have your oncologist submit a "continuity of care request" citing New Jersey regulations and your active treatment status.

Counterforce Health helps patients navigate these complex coverage transitions by turning insurance denials into targeted appeals. The platform analyzes denial letters and plan policies to identify the specific basis for denial, then drafts evidence-backed appeals aligned to each payer's own rules and New Jersey's patient protection laws.

Cancer Patient Care and Compassion Act: Proposed legislation would provide additional protections for Stage III and IV cancer patients, including employment protections and mandatory coverage for survivorship care.

FAQ

How long does UnitedHealthcare prior authorization take for Alecensa in New Jersey? Under New Jersey's 2025 law, UnitedHealthcare must respond within 24 hours for urgent requests and 72 hours for non-urgent requests. NCCN-compliant regimens with complete documentation often get approved faster.

What if Alecensa isn't on UnitedHealthcare's formulary? You can request a formulary exception by demonstrating medical necessity and clinical superiority over covered alternatives. New Jersey's step therapy protections also apply to non-formulary drugs when covered alternatives are inappropriate.

Can I request an expedited appeal if denied? Yes, expedited appeals are available when delays could cause serious harm to your health. Mark all requests as "urgent" and provide documentation of the time-sensitive nature of your cancer treatment.

Does step therapy apply if I tried other ALK inhibitors outside New Jersey? Yes, treatment history from other states counts toward step therapy requirements. Provide complete medical records showing prior failures or contraindications regardless of where treatment occurred.

What happens if UnitedHealthcare misses the 24-hour deadline? File a complaint with the New Jersey Department of Banking and Insurance. Missed deadlines can strengthen your case for appeals and may result in regulatory action against the insurer.

How much does Alecensa cost without insurance? The wholesale acquisition cost is approximately $19,466 per 240-count bottle (30-day supply). Genentech offers patient assistance programs that may reduce out-of-pocket costs.

Can my doctor file appeals on my behalf? Yes, providers can file appeals with your written consent. Many oncology practices have dedicated staff to handle prior authorizations and appeals for cancer medications like Alecensa.

What if I have a self-funded employer plan through UnitedHealthcare? Self-funded plans may not be subject to all New Jersey state protections due to federal ERISA laws. However, many voluntarily follow state guidelines, and federal appeal rights still apply.

From our advocates: We've seen New Jersey patients successfully overturn Alecensa denials by combining strong clinical documentation with citations to the state's new step therapy law. One common pattern: initial denials get reversed quickly when providers specifically reference Assembly Bill A1825 and document why alternatives would be medically inappropriate. The key is being specific about clinical contraindications rather than general preference statements.

When navigating complex prior authorization requirements, Counterforce Health provides specialized support by analyzing your specific denial and plan policies to craft targeted appeals that address UnitedHealthcare's exact concerns while leveraging New Jersey's patient protection laws.

Sources & Further Reading

Disclaimer: This information is for educational purposes only and does not constitute medical or legal advice. Insurance coverage varies by plan type and individual circumstances. Always consult with your healthcare provider and insurance plan directly for specific coverage decisions. For personalized assistance with New Jersey insurance appeals, contact the Department of Banking and Insurance Consumer Hotline at 1-800-446-7467.

Powered by Counterforce Health—AI that turns drug denials into evidence-based appeals patients and clinicians can submit today.